Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Stefan Ryser
AddedMar 31, 2024
UpdatedMay 31, 2026
Stefan Ryser

Stefan Ryser

CEO, Trellis Health Ventures

CrunchbaseLinkedIn

Stefan Ryser's Career

Trellis Health Ventures
Trellis Health Ventures

San Francisco, CA, US

CEO· C-Suite · Management
Trellis Bioscience
Trellis Bioscience

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Stefan Ryser's Career

Trellis Health Ventures
Trellis Health Ventures
Investment FirmInvestment Firm71998San Francisco, CA, US
CEO· C-Suite · Management

Leadership at Trellis Health Ventures

Larry KauvarLarry KauvarFounder
Trellis Bioscience
Trellis Bioscience
Seed$28.6M751998San Francisco, CA, US
Board Member· Board

Leadership at Trellis Bioscience

Somu SubramaniamSomu SubramaniamBoard Member
Stote EllsworthStote EllsworthBoard Member
Lawrence KauvarLawrence KauvarFounder
Tom LavinTom LavinBoard Member
John H. FriedmanJohn H. FriedmanBoard Member
Jon Sheldon SaxeJon Sheldon SaxeBoard Member

Similar to Trellis Bioscience

Treeline BiosciencesTreeline BiosciencesStamford, CT, USPrecision Medicinesest. 2021Treeline BiosciencesStamford, CT, US · est. 2021

Treeline Biosciences: A biotech firm creating precision medicines for serious conditions.

Series A · $473.3M166
TRex BioTRex BioSouth San Francisco, CA, USTherapeuticsest. 2018TRex BioSouth San Francisco, CA, US · est. 2018

TRexBio: A biotech firm innovating cancer and inflammatory disease therapeutics using advanced computational biology.

Series A · $85M69
TrelysTrelysSan Francisco, CA, USBiotechnologyest. 2012TrelysSan Francisco, CA, US · est. 2012

Trelys, Inc.: A San Francisco-based biotechnology company, innovating since 2012.

Seed · $2.6M30
Dren BioDren BioFoster City, CA, USTherapeutic Antibodiesest. 2019Dren BioFoster City, CA, US · est. 2019

Dren Bio: A biotech firm in San Carlos, CA, innovating protein-based solutions for disease treatment.

Series B · $130.1M63

Stefan Ryser's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuLee Sirg-OoLee Sirg-OoCEO · DunamuIn-hyuk ChoiIn-hyuk ChoiCEO · Naver FinancialWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Stefan Ryser

Maxim MikheevMaxim MikheevFounder & CEO · BiomedicanJeremy Curnock CookJeremy Curnock CookBoard Member · BioScience ManagersKevin ScanlonKevin ScanlonBoard Member · Pasadena AngelsVenkat KrishnanVenkat KrishnanCEO · BionpharmaTom RobertsTom RobertsCEO · New Republic PartnersJohn RomansJohn RomansCEO · Biomedix Vascular Solutions